Skip to main content

Bridge 2018: trends in cancer immunotherapy

By 7 Dicembre 2018Aprile 7th, 2021No Comments
Dai congressi

Lisa H. Butterfield, Professor of Medicine, Surgery and Immunology at the University of Pittsburgh and Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the University of Pittsburgh Cancer Institute (UPCI), is the President of Society of ImmunoTherapy of Cancer (SITC) and makes for us an assessment of the two days of “Immunotherapy Bridge” congress.